16 citations
,
January 2011 in “International Journal of Trichology”
This article discusses the principles and considerations of clinical photography for hair disorders in dermatology, reporting no new clinical findings.
This study found that 54% of participants with androgenetic alopecia using Ricapil® showed clinical signs of hair follicle reactivation and initial hair regrowth over three months.
This study found that sensor-controlled scalp cooling prevented visible hair loss in 53% of breast cancer patients undergoing chemotherapy, with greater hair density and absence of comorbidities enhancing its efficacy, also improving patients' quality of life without increasing scalp metastasis risk.
This consensus from 22 Spanish dermatologists recommends using a multimodal therapy starting with oral dutasteride, combined with topical and/or intralesional agents, and adding hydroxychloroquine if inflammation persists, to manage frontal fibrosing alopecia due to its irreversible hair loss and lack of specific approved treatments.
This study reviewed current scientific evidence on the use of exosomes for treating alopecias, finding they may stimulate dermal papilla cell proliferation and modulate inflammation, though challenges in standardization and long-term efficacy remain.
What do clinical trials say about the safety and effectiveness of SCUBE3 for hair regrowth?No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.
Are there any clinical studies supporting follistatin as a hair loss treatment?There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.
David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.
Hair serums like The Ordinary and Vichy are seen as minor additions to hair loss treatments but are not considered effective on their own compared to well-studied options like Minoxidil and Finasteride. They may improve scalp health or hair strand quality but are not reliable for significant hair regrowth or combating male pattern baldness.
The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
The post and conversation discuss the link between DHT (a hormone), scalp itchiness, and hair loss. Some users share their experiences and treatments, including the use of fluconazole, corticosteroids, and ketoconazole shampoo, with one user suspecting minoxidil as a potential cause of their symptoms.